Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 9
2004 12
2005 13
2006 5
2007 10
2008 13
2009 13
2010 17
2011 20
2012 20
2013 14
2014 11
2015 22
2016 23
2017 23
2018 38
2019 32
2020 42
2021 58
2022 47
2023 59
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

461 results

Results by year

Filters applied: . Clear all
Page 1
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.
Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, Mikesch JH, Steffen B, Sauer T, Hanoun M, Schafer-Eckart K, Krause SW, Hanel M, Einsele H, Jost E, Brummendorf TH, Scholl S, Hochhaus A, Neubauer A, Burchert A, Kaufmann M, Niemann D, Schaich M, Blau W, Kiani A, Gorner M, Kaiser U, Kullmer J, Weber T, Berdel WE, Ehninger G, Muller-Tidow C, Platzbecker U, Serve H, Bornhauser M, Rollig C, Baldus CD, Fransecky L. Baden D, et al. Among authors: muller tidow c. Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285225. Online ahead of print. Haematologica. 2024. PMID: 38654660
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Röllig C, Schliemann C, Ruhnke L, Fransecky L, Heydrich BN, Hanoun M, Noppeney R, Schäfer-Eckart K, Wendelin K, Mikesch JH, Middeke JM, Reimann M, Fiebig F, Zukunft S, Wermke M, Serve H, Platzbecker U, Müller-Tidow C, Baldus CD, Bornhäuser M. Röllig C, et al. Among authors: muller tidow c. Br J Haematol. 2024 Apr 9. doi: 10.1111/bjh.19436. Online ahead of print. Br J Haematol. 2024. PMID: 38593353
Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study.
Korell F, Entenmann L, Romann S, Giannitsis E, Schmitt A, Müller-Tidow C, Frey N, Dreger P, Schmitt M, Lehmann LH. Korell F, et al. Among authors: muller tidow c. EClinicalMedicine. 2024 Feb 27;69:102504. doi: 10.1016/j.eclinm.2024.102504. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38544797 Free PMC article.
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence.
Eckardt JN, Hahn W, Röllig C, Stasik S, Platzbecker U, Müller-Tidow C, Serve H, Baldus CD, Schliemann C, Schäfer-Eckart K, Hanoun M, Kaufmann M, Burchert A, Thiede C, Schetelig J, Sedlmayr M, Bornhäuser M, Wolfien M, Middeke JM. Eckardt JN, et al. Among authors: muller tidow c. NPJ Digit Med. 2024 Mar 20;7(1):76. doi: 10.1038/s41746-024-01076-x. NPJ Digit Med. 2024. PMID: 38509224 Free PMC article.
Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
Felipe Fumero E, Walter C, Frenz JM, Seifert FC, Alla V, Hennig T, Angenendt L, Hartmann W, Wolf S, Serve H, Oellerich T, Lenz G, Müller-Tidow C, Schliemann C, Huber O, Dugas M, Mann M, Jayavelu AK, Mikesch JH, Arteaga MF. Felipe Fumero E, et al. Among authors: muller tidow c. Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640. Online ahead of print. Blood. 2024. PMID: 38457355 Free article.
N-MYC regulates cell survival via eIF4G1 in inv(16) acute myeloid leukemia.
Peramangalam PS, Surapally S, Veltri AJ, Zheng S, Burns R, Zhu N, Rao S, Muller-Tidow C, Bushweller JH, Pulikkan JA. Peramangalam PS, et al. Among authors: muller tidow c. Sci Adv. 2024 Mar;10(9):eadh8493. doi: 10.1126/sciadv.adh8493. Epub 2024 Feb 28. Sci Adv. 2024. PMID: 38416825 Free PMC article.
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Eissymont O, Crysandt M, Görner M, Kayser S, Krause S, Schliemann C, Gaska T, Kaufmann M, Chemnitz J, Schaich M, Hoellein A, Platzbecker U, Kieser M, Müller-Tidow C, Schlenk RF. Jaramillo S, et al. Among authors: muller tidow c. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284346. Online ahead of print. Haematologica. 2024. PMID: 38385304 Free article.
Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities.
Roider T, Baertsch MA, Fitzgerald D, Vöhringer H, Brinkmann BJ, Czernilofsky F, Knoll M, Llaó-Cid L, Mathioudaki A, Faßbender B, Herbon M, Lautwein T, Bruch PM, Liebers N, Schürch CM, Passerini V, Seifert M, Brobeil A, Mechtersheimer G, Müller-Tidow C, Weigert O, Seiffert M, Nolan GP, Huber W, Dietrich S. Roider T, et al. Among authors: muller tidow c. Nat Cell Biol. 2024 Mar;26(3):478-489. doi: 10.1038/s41556-024-01358-2. Epub 2024 Feb 20. Nat Cell Biol. 2024. PMID: 38379051 Free PMC article.
461 results